Mereo to Appoint Four New Directors to its Board of Directors

See more here:
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management

TORONTO, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company inspiring and empowering the worldwide community to live their very best life today announced the expansion of Good Supply’s award-winning cannabis portfolio. The brand’s latest product release includes the launch of new high-potency strains and expanded distribution of its new bestselling products across Canada.

More here:
Good Supply Cannabis Brand Reveals New Fall Flower Launches and Expands Distribution of Bestselling High-Potency Products

SAN MATEO, Calif. and SINGAPORE, Oct. 28, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced financial results for the third quarter ended September 30, 2022, and provided an update on recent corporate activities.

Excerpt from:
ASLAN Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Since launch the new product has had approximately 117% ROI

Link:
SciSparc: Wellution™ Successfully Launched a New Keto Gummies Apple Cider Vinegar Product and Generated $100,000 In Revenues Within 30 Days

TORONTO and HOUSTON, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that on October 25, 2022, it received a notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”), stating that the Company is not in compliance with the minimum bid price requirement ("Minimum Bid Requirement") of US$1.00 per share under the Nasdaq Listing Rule 5450(a)(1) based upon the closing bid price of the Company’s common stock for the 30 consecutive business days prior to the date of the Notice. The Notice has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq, and the Company’s operations are not affected by the receipt of the Notice.

Read the rest here:
Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

GAITHERSBURG, Md., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the Company will be presenting at two upcoming scientific conferences in November 2022:

Read more:
Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting®

New Orleans, Louisiana, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Software Effective Solutions Corporation (OTC: SFWJ) (“The Company”, “SFWJ”) subsidiary Medcana is pleased to announce the successful launch of test greenhouses for microclimates and genetics with five partner firms in Colombia, South America. With significantly better economics than the US and Canada, a central location for exportation to major markets, and prime cultivation characteristics, Colombia is believed by many to have significant cultivation advantages over other regions around the world.

Read the original:
Correction: Software Effective Solutions Subsidiary MEDCANA (OTC: SFWJ) Announces Successful Launch of Test Greenhouses for Microclimates and Genetics...

ISELIN, N.J., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a Biologics License Application (BLA) for ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD). The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023. ONS-5010, if approved, is expected to receive 12 years of regulatory exclusivity in the United States.

View post:
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

ESTERO, Fla., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Marijuana Strategic Ventures, Inc. (the “Company”)(OTC: MSVI) now Mushrooms Inc., Announces Positioning for Global Acquisitions and Shareholder Update.

Go here to see the original:
Marijuana Strategic Ventures, Inc. (OTC: MSVI) Now Mushrooms Inc., Announces Positioning for Global Acquisitions and Shareholder Update

Media Release

The rest is here:
Genmab Announces Submissions of Regulatory Applications for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell...

Negma Group has converted 580 convertible bonds in Oxurion resulting in a EUR 1,450,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.

Read the original post:
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA

28.10.2022 at 18:30

See the rest here:
Orion Corporation: Acquisition of Own Shares 28.10.2022

FDA Issues Deferred Action Letter on AT-GAA Regulatory Filing Due to the Inability to Conduct Required Manufacturing Site Inspection Prior to the PDUFA Action Date

Read this article:
U.S. FDA Defers Action on Filing for AT-GAA in Late-onset Pompe Disease

NEW YORK, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced the outcome of the meeting of the U.S. Food and Drug Administration (“FDA”) Oncologic Drugs Advisory Committee (“ODAC”), which reviewed investigational 131I-omburtamab (“omburtamab”) for the treatment of CNS/leptomeningeal metastasis from neuroblastoma. The committee voted 16 to 0 that the Company had not provided sufficient evidence to conclude that omburtamab improves overall survival.

Excerpt from:
Y-mAbs Announces Outcome of FDA Advisory Committee Meeting on Omburtamab

Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options Company is currently engaged in a strategic review process, evaluating additional development of its assets, collaborations and other strategic options

Excerpt from:
ARCA biopharma Announces Third Quarter 2022 Financial Results

Company to complete and submit responses to FDA clinical hold

Originally posted here:
CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues

NEW YORK and LONDON, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Akari received a letter from Nasdaq Listing Qualifications indicating that Akari is not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share.

Read the rest here:
Akari Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification

PORTLAND, Ore., Oct. 28, 2022 (GLOBE NEWSWIRE) -- Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) (the “Company” or “Chalice Brands”), a premier consumer-driven cannabis company specializing in retail, production, processing, wholesale, and distribution, announces that its interim Chief Financial Officer (CFO), Richard Lindsay, has resigned his position. Mr. Lindsay joined the company in an interim contract role to help get the Company through the 2021 audit. He has accomplished the majority of the work related to the audit and accordingly has resigned his position.

Continued here:
Chalice Brands Ltd. Announces Resignation of Interim Chief Financial Officer

NEW HAVEN, Conn., Oct. 28, 2022 (GLOBE NEWSWIRE) --  BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factors and a differentiated, proprietary xB3 ™ platform for delivering therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, today announced it has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended August 31, 2022. All are available under the Company’s profile on SEDAR at www.sedar.com and on the Company’s website at www.bioasis.us.

View original post here:
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2022

SAN FRANCISCO, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter ended September 30, 2022, on Thursday, November 3, 2022.

See original here:
Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022